Matinas BioPharma Holdings (MTNB) Amortizatization of Intangibles (2018 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Amortizatization of Intangibles of $1000.0 for Q4 2025, up 104.76% year-over-year from $488.37 in Q4 2024, and little changed quarter-over-quarter from $1000.0 in Q3 2025.
Matinas BioPharma Holdings (MTNB) Amortizatization of Intangibles (2018 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Amortizatization of Intangibles for 8 consecutive years, with $1000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Amortizatization of Intangibles rose 104.76% year-over-year to $1000.0; the TTM figure through Dec 2025 stood at $4000.0 (up 123.53% YoY), while the FY2025 annual figure was $4000.0, up 123.53% from the prior year.
- Amortizatization of Intangibles held at $1000.0 in Q4 2025 per MTNB's latest filing, from $1000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $220700.0 in Q4 2021 and bottomed at -$21000.0 in Q4 2024.
- Historically, Amortizatization of Intangibles has averaged $22297.6 across 5 years, with a median of $2500.0 in 2022.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles soared 2400.0% — and 2024, when it tumbled 121.0%.
- Matinas BioPharma Holdings' Amortizatization of Intangibles stood at $220700.0 in 2021, then slumped by 98.19% to $4000.0 in 2022, then jumped by 2400.0% to $100000.0 in 2023, then sank by 121.0% to -$21000.0 in 2024, then surged by 104.76% to $1000.0 in 2025.
- Business Quant data shows MTNB's Amortizatization of Intangibles at $1000.0 in Q4 2025, $1000.0 in Q3 2025, and $1000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - | 3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,000.00 |
| Jun 30, 2026 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | -21,000.00 |
| Dec 31, 2024 | -21,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Dec 31, 2023 | 100,000.00 |
| Dec 31, 2023 | 100,000.00 |